Pharmaceuticals

Global Peptide Based Metabolic Disorders Therapeutics Market Trends and Growth Analysis 2025–2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Peptide Based Metabolic Disorders Therapeutics Industry Compare Between 2025 And 2029?

The peptide based metabolic disorders therapeutics market size has experienced significant growth in recent years. It is anticipated to expand from $29.89 billion in 2024 to $34.1 billion in 2025, at a compound annual growth rate (CAGR) of 14.1%. Historically, this expansion has been driven by factors such as the increasing prevalence of metabolic disorders, advancements in peptide synthesis technologies, rising healthcare expenditure, a growing aging population, an expanding biopharmaceutical sector, regulatory approvals for new therapies, and increasing awareness about personalized medicine.

The peptide based metabolic disorders therapeutics market is projected to experience substantial expansion in the coming years, reaching $57.13 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.8%. This anticipated growth during the forecast period is fueled by several factors, including the creation of new peptide analogs, increased R&D spending on metabolic disorders, the adoption of precision medicine, the expansion into developing markets, strategic collaborations and partnerships in drug development, innovations in drug delivery technologies, and an emphasis on patient-centered treatments. Key trends expected over this period encompass the use of artificial intelligence in drug discovery, the rise of individualized treatments, the application of CRISPR/Cas9 for gene therapies, the incorporation of wearable technologies for patient oversight, the creation of oral peptide forms, the emergence of digital therapeutics for disease management, and the growth of biobanking for tailored treatments.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp

Which Industry Drivers Are Expected To Accelerate The Peptide Based Metabolic Disorders Therapeutics Market From 2025 To 2029?

The increasing occurrence of obesity is projected to drive the expansion of the peptide-based metabolic disorders therapeutic market in the future. Obesity is a medical condition marked by an excessive accumulation of body fat, which poses significant health risks. The growing number of obesity cases can be attributed to sedentary lifestyles, unhealthy dietary choices, genetic predispositions, and environmental factors that foster calorie-rich diets and a lack of physical activity. Peptide-based metabolic disorders therapeutics aim to manage conditions like obesity by utilizing peptides to regulate metabolic functions, enhance insulin sensitivity, and control appetite, thereby improving patient health outcomes and lessening long-term health risks associated with these chronic disorders. For instance, in April 2024, The British Diabetic Association, a UK-based healthcare professional and research charity, reported that in the UK, 4.4 million people are living with diabetes, and an estimated 1.2 million more may have undiagnosed type 2 diabetes. The 2022-23 registration figures showed an increase of 167,822 from 2021-22. As a result, the rising prevalence of obesity is a key driver for the peptide-based metabolic disorder therapeutics market.

What Are The Major Segment Types Covered In The Peptide Based Metabolic Disorders Therapeutics Market?

The peptide based metabolic disorders therapeutics market covered in this report is segmented –

1) By Drug Type: Liraglutide, Exenatide, Other Drug Type

2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity

2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide

3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders

Which Key Trends Are Expected To Influence The Peptide Based Metabolic Disorders Therapeutics Market In The Coming Years?

Leading companies in the peptide-based therapeutics market for metabolic disorders are actively developing advanced peptide-based treatments, such as anti-diabetic biosimilars, aiming to address unmet medical needs and expand patient therapy options. Peptide-based anti-diabetic biosimilars are therapeutic medications designed to mimic existing peptide-based diabetes treatments, delivering comparable efficacy and safety profiles to established drugs, while potentially reducing treatment costs through competitive pricing strategies. For example, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Lirafit in India, a biosimilar version of the popular anti-diabetic drug Liraglutide. This product is categorized as a glucagon-like peptide-1 receptor agonist (GLP-1 RA). This class of drugs imitates the action of the naturally occurring GLP-1 hormone, which plays a critical role in regulating blood sugar levels. Clinical trials have demonstrated this biosimilar’s effectiveness in lowering glycemic parameters, promoting weight reduction, and enhancing cardiovascular safety. These represent significant benefits for managing diabetes and associated conditions, including obesity and cardiovascular diseases.

Which Global Market Leaders Are Shaping The Future Of The Peptide Based Metabolic Disorders Therapeutics Sector?

Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

How Does The Peptide Based Metabolic Disorders Therapeutics Market Perform Across Key Geographic Regions?

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Peptide Based Metabolic Disorders Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp

Browse Through More Reports Similar to the Global Peptide Based Metabolic Disorders Therapeutics Market 2025, By The Business Research Company

Microbiome Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Neurodegenerative Disorder Therapeutic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Antisense And Rnai Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795